FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973602287> ?p ?o ?g. }

• W2973602287 endingPage "579" @default.
• W2973602287 startingPage "567" @default.
• W2973602287 abstract "The prime issue derived from prostate cancer (PCa) is its high prevalence to metastasize to bone. MicroRNA-204-5p (miR-204-5p) has been reported to be involved in the development and metastasis in a variety of cancers. However, the clinical significance and biological functions of miR-204-5p in bone metastasis of PCa are still not reported yet. In this study, we find that miR-204-5p expression is reduced in PCa tissues and serum sample with bone metastasis compared with that in PCa tissues and serum sample without bone metastasis, which is associated with advanced clinicopathological characteristics and poor bone metastasis-free survival in PCa patients. Moreover, upregulation of miR-204-5p inhibits the migration and invasion of PCa cells in vitro, and importantly, upregulating miR-204-5p represses bone metastasis of PCa cells in vivo. Our results further demonstrated that miR-204-5p suppresses invasion, migration, and bone metastasis of PCa cells via inactivating nuclear factor κB (NF-κB) signaling by simultaneously targeting TRAF1, TAB3, and MAP3K3. In clinical PCa samples, miR-204-5p expression negatively correlates with TRAF1, TAB3, and MAP3K3 expression and NF-κB signaling activity. Therefore, our findings reveal a new mechanism underpinning the bone metastasis of PCa, as well as provide evidence that miR-204-5p might serve as a novel serum biomarker in bone metastasis of PCa.This study identifies a novel functional role of miR-204-5p in bone metastasis of prostate cancer and supports the potential clinical value of miR-204-5p as a serum biomarker in bone metastasis of PCa. The prime issue derived from prostate cancer (PCa) is its high prevalence to metastasize to bone. MicroRNA-204-5p (miR-204-5p) has been reported to be involved in the development and metastasis in a variety of cancers. However, the clinical significance and biological functions of miR-204-5p in bone metastasis of PCa are still not reported yet. In this study, we find that miR-204-5p expression is reduced in PCa tissues and serum sample with bone metastasis compared with that in PCa tissues and serum sample without bone metastasis, which is associated with advanced clinicopathological characteristics and poor bone metastasis-free survival in PCa patients. Moreover, upregulation of miR-204-5p inhibits the migration and invasion of PCa cells in vitro, and importantly, upregulating miR-204-5p represses bone metastasis of PCa cells in vivo. Our results further demonstrated that miR-204-5p suppresses invasion, migration, and bone metastasis of PCa cells via inactivating nuclear factor κB (NF-κB) signaling by simultaneously targeting TRAF1, TAB3, and MAP3K3. In clinical PCa samples, miR-204-5p expression negatively correlates with TRAF1, TAB3, and MAP3K3 expression and NF-κB signaling activity. Therefore, our findings reveal a new mechanism underpinning the bone metastasis of PCa, as well as provide evidence that miR-204-5p might serve as a novel serum biomarker in bone metastasis of PCa. This study identifies a novel functional role of miR-204-5p in bone metastasis of prostate cancer and supports the potential clinical value of miR-204-5p as a serum biomarker in bone metastasis of PCa." @default.
• W2973602287 created "2019-09-26" @default.
• W2973602287 creator A5012937567 @default.
• W2973602287 creator A5015839949 @default.
• W2973602287 creator A5027628707 @default.
• W2973602287 creator A5029614105 @default.
• W2973602287 creator A5032969594 @default.
• W2973602287 creator A5034654778 @default.
• W2973602287 creator A5051759102 @default.
• W2973602287 creator A5054751043 @default.
• W2973602287 creator A5060655064 @default.
• W2973602287 creator A5071986353 @default.
• W2973602287 creator A5073012649 @default.
• W2973602287 creator A5076432479 @default.
• W2973602287 creator A5082292647 @default.
• W2973602287 creator A5085375696 @default.
• W2973602287 date "2019-12-01" @default.
• W2973602287 modified "2023-10-14" @default.
• W2973602287 title "miR-204-5p Represses Bone Metastasis via Inactivating NF-κB Signaling in Prostate Cancer" @default.
• W2973602287 cites W1532865172 @default.
• W2973602287 cites W1537186317 @default.
• W2973602287 cites W1575383081 @default.
• W2973602287 cites W1600472471 @default.
• W2973602287 cites W1736623295 @default.
• W2973602287 cites W1824707126 @default.
• W2973602287 cites W1884264718 @default.
• W2973602287 cites W1978701756 @default.
• W2973602287 cites W1980036425 @default.
• W2973602287 cites W1988924112 @default.
• W2973602287 cites W1995747121 @default.
• W2973602287 cites W2013391574 @default.
• W2973602287 cites W2014923657 @default.
• W2973602287 cites W2026000570 @default.
• W2973602287 cites W2037454778 @default.
• W2973602287 cites W2056402897 @default.
• W2973602287 cites W2066713051 @default.
• W2973602287 cites W2070782085 @default.
• W2973602287 cites W2072130349 @default.
• W2973602287 cites W2073983559 @default.
• W2973602287 cites W2078628959 @default.
• W2973602287 cites W2078960019 @default.
• W2973602287 cites W2088393064 @default.
• W2973602287 cites W2088633139 @default.
• W2973602287 cites W2094863064 @default.
• W2973602287 cites W2099480372 @default.
• W2973602287 cites W2101587940 @default.
• W2973602287 cites W2104153960 @default.
• W2973602287 cites W2106419040 @default.
• W2973602287 cites W2109333569 @default.
• W2973602287 cites W2109465104 @default.
• W2973602287 cites W2111608545 @default.
• W2973602287 cites W2134887638 @default.
• W2973602287 cites W2152038469 @default.
• W2973602287 cites W2162332085 @default.
• W2973602287 cites W2168384602 @default.
• W2973602287 cites W2183877552 @default.
• W2973602287 cites W2225630564 @default.
• W2973602287 cites W2315613727 @default.
• W2973602287 cites W2501242136 @default.
• W2973602287 cites W2518602763 @default.
• W2973602287 cites W2586917323 @default.
• W2973602287 cites W2586938441 @default.
• W2973602287 cites W2588057136 @default.
• W2973602287 cites W2594720997 @default.
• W2973602287 cites W2597828960 @default.
• W2973602287 cites W2615504024 @default.
• W2973602287 cites W2626034093 @default.
• W2973602287 cites W2729169242 @default.
• W2973602287 cites W2731346561 @default.
• W2973602287 cites W2734757171 @default.
• W2973602287 cites W2736513415 @default.
• W2973602287 cites W2748631433 @default.
• W2973602287 cites W2750892432 @default.
• W2973602287 cites W2756442362 @default.
• W2973602287 cites W2766691522 @default.
• W2973602287 cites W2769530685 @default.
• W2973602287 cites W2771436561 @default.
• W2973602287 cites W2778639348 @default.
• W2973602287 cites W2783383541 @default.
• W2973602287 cites W2788424237 @default.
• W2973602287 cites W2806461678 @default.
• W2973602287 cites W2911662030 @default.
• W2973602287 cites W2992141400 @default.
• W2973602287 doi "https://doi.org/10.1016/j.omtn.2019.09.008" @default.
• W2973602287 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6838892" @default.
• W2973602287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31678733" @default.
• W2973602287 hasPublicationYear "2019" @default.
• W2973602287 type Work @default.
• W2973602287 sameAs 2973602287 @default.
• W2973602287 citedByCount "41" @default.
• W2973602287 countsByYear W29736022872020 @default.
• W2973602287 countsByYear W29736022872021 @default.
• W2973602287 countsByYear W29736022872022 @default.
• W2973602287 countsByYear W29736022872023 @default.
• W2973602287 crossrefType "journal-article" @default.
• W2973602287 hasAuthorship W2973602287A5012937567 @default.
• W2973602287 hasAuthorship W2973602287A5015839949 @default.
• W2973602287 hasAuthorship W2973602287A5027628707 @default.

• next